Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 2 |
2004 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
Antiprotease Cohort (proc) study group[Corporate Author]
(2 results)?
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1.
Clin Infect Dis. 2004.
PMID: 15307035
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group.
Le Moing V, et al.
J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008.
J Acquir Immune Defic Syndr. 2003.
PMID: 14657760
Item in Clipboard
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.
Duran S, Peytavin G, Carrieri P, Raffi F, Ecobichon JL, Pereira E, Cassuto GP, Spire B, Leport C; Antiprotease Cohort (APROCO) study group.
Duran S, et al.
AIDS. 2003 May 2;17(7):1096-9. doi: 10.1097/00002030-200305020-00025.
AIDS. 2003.
PMID: 12700466
Item in Clipboard
Cite
Cite